Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Net Cash Flow data on file, last reported at -$66.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 23.36% year-over-year to -$66.7 million; the trailing twelve-month figure through Mar 2026 stood at -$231.8 million (down 169.04% YoY), and the FY2025 full-year result was -$252.2 million, down 171.27% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$66.7 million, down from -$19.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $504.6 million in Q2 2024 and bottomed at -$87.0 million in Q1 2025.
• The 5-year median for Net Cash Flow is -$33.1 million (2022), against an average of $7.2 million.
• The widest annual swing landed in 2022, when Net Cash Flow slumped 1200.46%; it then surged 2780.59% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$25.9 million in 2022, then sank by 81.5% to -$47.0 million in 2023, then soared by 79.64% to -$9.6 million in 2024, then tumbled by 108.5% to -$19.9 million in 2025, then sank by 234.55% to -$66.7 million in 2026.
• The last three Net Cash Flow figures came in at -$66.7 million (Q1 2026), -$19.9 million (Q4 2025), and -$71.9 million (Q3 2025), per Business Quant data.

Peer Comparison